Regulatory Environment Analysis Clause Samples

Regulatory Environment Analysis. In coordination with the City’s current zoning update initiative, the Consultant Team will review and analyze existing land use codes for the corridor to determine areas for improvement and make recommendations for policy and code changes. Zoning overlays should also be addressed in this analysis, with an emphasis on Form-Based Code. Deliverables: • Summary of Market Demand and Redevelopment Incentives Analysis • Summary of Redevelopment Opportunities and Challenges Analysis • Summary of Regulatory Environment Analysis • Recommendations from Land-Use Analysis • Zoning and Development Code Review and Analysis • Proposed Zoning Overlays including Recommendations for Modifications and/or Proposed Development Incentives/Strategies • Form-Based Code Recommendations The Consultant Team will prepare a Draft Division Street Corridor Master Plan document compiling the work outlined in the previous tasks. The following will be included: • Case studies of successful programs and implementation strategies pertinent to the City of Arlington • Existing Conditions Analysis • Transportation Infrastructure Improvement Analysis • Land Use Revitalization Strategies • Implementation Plan and Table of Action Steps • Appendices including public input summaries, cost estimates, maps, etc. The Consultant Team will submit the draft plan to the DCAC, PRC, and the public for review. The final draft plan will be made available in paper and digital form. The digital form will be made available on the project website for easy download. Deliverables: • Draft plan (digital and hardcopy) The Plan should integrate comments from focus group and public meetings. The Plan should include, but is not limited to the following: an acknowledgment page, a table of contents, list of figures and tables, an executive summary, the findings of all the tasks in Phase One through Five, conclusion, appendices, and a glossary. The PRC will review the document and provide comments before the consultant finalizes the plan. The report will be high-quality with clear images and illustrations with written text that is free of typographical and grammatical errors. All maps and tables will be properly cited and contain keys when appropriate. The consultant will apply its internal quality assurance controls to achieve a high quality report. Neither NCTCOG nor the City of Arlington will undertake quality control for the report. The Consultant Team will provide a series of documents and materials that can be used to ...
View Source

Related to Regulatory Environment Analysis

  • Risk Analysis The Custodian will provide the Fund with a Risk Analysis with respect to Securities Depositories operating in the countries listed in Appendix B. If the Custodian is unable to provide a Risk Analysis with respect to a particular Securities Depository, it will notify the Fund. If a new Securities Depository commences operation in one of the Appendix B countries, the Custodian will provide the Fund with a Risk Analysis in a reasonably practicable time after such Securities Depository becomes operational. If a new country is added to Appendix B, the Custodian will provide the Fund with a Risk Analysis with respect to each Securities Depository in that country within a reasonably practicable time after the addition of the country to Appendix B.

  • Investment Analysis and Implementation In carrying out its obligations under Section 1 hereof, the Advisor shall: (a) supervise all aspects of the operations of the Funds; (b) obtain and evaluate pertinent information about significant developments and economic, statistical and financial data, domestic, foreign or otherwise, whether affecting the economy generally or the Funds, and whether concerning the individual issuers whose securities are included in the assets of the Funds or the activities in which such issuers engage, or with respect to securities which the Advisor considers desirable for inclusion in the Funds' assets; (c) determine which issuers and securities shall be represented in the Funds' investment portfolios and regularly report thereon to the Board of Trustees; (d) formulate and implement continuing programs for the purchases and sales of the securities of such issuers and regularly report thereon to the Board of Trustees; and (e) take, on behalf of the Trust and the Funds, all actions which appear to the Trust and the Funds necessary to carry into effect such purchase and sale programs and supervisory functions as aforesaid, including but not limited to the placing of orders for the purchase and sale of securities for the Funds.

  • Escrow Analysis If applicable, with respect to each Mortgage Loan, the Seller has within the last twelve months (unless such Mortgage was originated within such twelve month period) analyzed the required Escrow Payments for each Mortgage and adjusted the amount of such payments so that, assuming all required payments are timely made, any deficiency will be eliminated on or before the first anniversary of such analysis, or any overage will be refunded to the Mortgagor, in accordance with RESPA and any other applicable law;

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.

  • Statistical Sampling Documentation a. A copy of the printout of the random numbers generated by the “Random Numbers” function of the statistical sampling software used by the IRO.‌ b. A description or identification of the statistical sampling software package used by the IRO.‌